CN107739361A - Come from aspergillus versicolor anthraquinone analog compound and prepare the application of anti-human colon cancer drug - Google Patents
Come from aspergillus versicolor anthraquinone analog compound and prepare the application of anti-human colon cancer drug Download PDFInfo
- Publication number
- CN107739361A CN107739361A CN201711079824.2A CN201711079824A CN107739361A CN 107739361 A CN107739361 A CN 107739361A CN 201711079824 A CN201711079824 A CN 201711079824A CN 107739361 A CN107739361 A CN 107739361A
- Authority
- CN
- China
- Prior art keywords
- compound
- human colon
- aspergillus versicolor
- colon cancer
- application
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D313/00—Heterocyclic compounds containing rings of more than six members having one oxygen atom as the only ring hetero atom
- C07D313/16—Eight-membered rings
- C07D313/20—Eight-membered rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P17/00—Preparation of heterocyclic carbon compounds with only O, N, S, Se or Te as ring hetero atoms
- C12P17/02—Oxygen as only ring hetero atoms
- C12P17/08—Oxygen as only ring hetero atoms containing a hetero ring of at least seven ring members, e.g. zearalenone, macrolide aglycons
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Wood Science & Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The present invention relates to come from aspergillus versicolor anthraquinone analog compound and prepare the application of anti-human colon cancer drug.The compound, which has, suppresses Colon Cancer Cells effect.Its structural formula is：.By fermented and cultured aspergillus versicolor (Aspergillus versicolor) IBPT 7, fermentate is obtained, the compound is then isolated and purified out from fermentate.It is verified by experiments, the compound has preferable antitumor activity to human colon cancer cell HCT 116.The research of medicine or antineoplastic for human colon carcinoma can be suppressed as Proliferation of Human Colon is prepared.
Description
Technical field
The invention belongs to biomedicine field, and in particular to one kind comes from aspergillus versicolor anthraquinone analog compound and prepared anti-human
The application of colon cancer drug.
Background technology
Anthraquinone analog compound exists extensively in natural drug and has important pharmacological effect, such as Chinese medicine sealwort, Asian puccoon, pellet
All contain a large amount of anthraquinone analog compounds in the plants such as ginseng, rheum officinale, tripterygium wilfordii, there are a variety of work(such as antitumor, antibacterial, anti-oxidant
Effect, particularly it is widely used in the preventing and treating of the major diseases such as cancer, angiocardiopathy, senile dementia, AIDS, achievement in research is many
It is more, by the common concern of global scientist and medical personage.Wherein in antitumor field, its mechanism of action, which is mainly manifested in, to lure
Lead apoptosis of tumor cells, the effect of reversing tumor cell multidrug resistance, enzyme inhibitor, the propagation and cell week for influenceing tumour cell
Phase, metabolism, the killing to tumour cell and the mutagenesis for suppressing tumour cell etc. are worked.Research in recent years shows that some oceans are true
Bacterium can also produce the anthraquinone analog compound that structure is novel, activity is good during cometabolism, have medicinal well and production
Industry prospect.
The present inventor's research is learnt, aspergillus versicolor, (has been deposited in Chinese Typical Representative culture guarantor on December 25th, 2013
Tibetan center, address:Wuhan Wuhan University, deposit number are：CCTCC NO：M 2013715) tunning coarse extraction
Thing has good cell inhibitory effect activity, and its active component is studied then.Research find shown in anthraquinone analog compound tool
There is anti-human colon cancer reactive, have not yet to see report of the compound to the proliferation inhibition activity of human colon cancer cell, therefore city
Also there is not yet medicine related to this on field.
The content of the invention
Aspergillus versicolor anthraquinone analog compound is come from it is an object of the invention to provide one kind and prepares anti-human colon cancer drug
Application.The compound, which has, suppresses Proliferation of Human Colon effect, has anti-human colon cancer reactive.Its structural formula is：
。
The preparation method of the compound, it is by fermented and cultured aspergillus versicolor, obtains fermentate, then divide from fermentate
From being purified into the compound.Comprise the following steps that：
1 fermenting and producing
The conventional method of microorganism is cultivated, takes aspergillus versicolor to be inoculated into PDA solid slope culture mediums and is trained in 28 DEG C of incubators
Support 2 to 3 days, be then seeded into SWS nutrient solutions, 28 DEG C of static gas wave refrigerators obtain 20 liters of mycelium and zymotic fluid after 30 days；It is described
Nutrient solution forms：Starch-containing 10.0 g of every liter of water, 20.0 g of g, NaCl of peptone 1.0.
The acquisition of 2 medicinal extract
By aspergillus versicolor fermentation culture (about 20 L), via being divided into mycelium and zymotic fluid two parts after filtered through gauze.Fermentation
Liquid part by volume 1:2 add ethyl acetate, through extracting twice, the acetic acid ethyl acetate extract of gained are merged and is concentrated under reduced pressure into
It is near dry, collect zymotic fluid ethyl acetate extract.Mycelium then with the aqueous solution ultrasonication 3 times of the acetone containing 70%-80%, removes residual
Slag clear liquid is merged after through be concentrated under reduced pressure remove acetone, be by volume 1:2 addition ethyl acetate are extracted twice, and are concentrated under reduced pressure into
It is near to do to obtain mycelium medicinal extract.Extract medicinal extract is obtained after zymotic fluid ethyl acetate extract and mycelium medicinal extract two parts are merged to be total to
6.0 g。
The separation and purification of 3 compounds
Medicinal extract（6.0 g）By 100-200 mesh silica gel mixed samples, with petroleum ether：Dichloromethane：Methanol is gradient eluent, is carried out
Depressurize silica gel chromatograph column chromatography.By simple thin-layer chromatographic analysis, merge, be separated into component A-F.Component E (1.1 g) (two
Chloromethanes：Methanol v/v=100:1 eluate) with dichloromethane：Methanol is gradient elution agent, carries out pressured column silica gel
Analysis, merge after thin-layer chromatographic analysis and obtain five subfraction E1-E5.Component E2 (0.3 g) is with chloroform：Methanol=
1:2 be eluant, eluent, carries out gel filtration chromatography（Sephadex LH-20）, merge after thin-layer chromatographic analysis and obtain four subgroups
Divide E2-1 ~ E2-4.E2 subfraction E2-2 (93 mg) by semi-preparative liquid chromatography (1010 type ODS-A, 10 × 250 mm,
5 μm)：Separation flow velocity is 5 mL/min, and mobile phase is that 75% acetonitrile contains 0.1% TFA, obtains shown compound (3.4 mg, tR
9.1 min)。
The aspergillus versicolor (Aspergillus versicolor) IBPT-7, it is deposited in on December 25th, 2013
China typical culture collection center, address:Wuhan Wuhan University, deposit number are：CCTCC NO：M 2013715.
The present invention also protects described compound preparing the application in suppressing Proliferation of Human Colon medicine, and should
Application of the compound in anti-human colon cancer drug is prepared.
The remarkable advantage of the present invention：The anthraquinone compounds shown in research have no report and suppress human colon carcinoma with significant
Proliferation activity, has not yet to see report of the compound to Proliferation of Human Colon inhibitory activity, in the market also there is not yet
Medicine related to this.
Brief description of the drawings
Main COSY, HMBC and the NOE signal of Fig. 1 compounds.
Embodiment
The chemical constitution of signified compound in examples below：
The fermenting and producing and separation and purification of the compound of embodiment 1
1 fermenting and producing
Produce the fermented and cultured of bacterium：By culture microorganism conventional method, take aspergillus versicolor (Aspergillus versicolor) IBPT-7 (is deposited in China typical culture collection center, address on December 25th, 2013:Wuhan
Wuhan University, deposit number are：CCTCC NO：M 2013715) in right amount, it is inoculated into PDA solid slope culture mediums at 28 DEG C
Cultivated 2 to 3 days in incubator.
Taking the inclined-plane culture aspergillus versicolor of 2 to 3 days appropriate, be inoculated into SWS nutrient solutions, 28 DEG C of static gas wave refrigerators are after 30 days,
Obtain mycelium and zymotic fluid 20L；The nutrient solution composition：Starch-containing 10.0 g of every liter of water, g, the NaCl 20.0 of peptone 1.0
g。
The acquisition of 2 medicinal extract
By aspergillus versicolor fermentation culture (about 20 L), via being divided into mycelium and zymotic fluid two parts after filtered through gauze.Fermentation
Liquid part by volume 1:2 add ethyl acetate, through extracting twice, the acetic acid ethyl acetate extract of gained are merged and is concentrated under reduced pressure into
It is near dry, collect zymotic fluid ethyl acetate extract.Mycelium then with the aqueous solution ultrasonication 3 times of the acetone containing 70%-80%, removes residual
Slag clear liquid is merged after through be concentrated under reduced pressure remove acetone, be by volume 1:2 addition ethyl acetate are extracted twice, and are concentrated under reduced pressure into
It is near to do to obtain mycelium medicinal extract.Extract medicinal extract is obtained after zymotic fluid ethyl acetate extract and mycelium medicinal extract two parts are merged to be total to
6.0 g。
The separation and purification of 3 compounds
Medicinal extract（6.0 g）By 100-200 mesh silica gel mixed samples, with petroleum ether：Dichloromethane：Methanol is gradient eluent, is carried out
Depressurize silica gel chromatograph column chromatography.By simple thin-layer chromatographic analysis, merge, be separated into component A-F.Component E (1.1 g) (two
Chloromethanes：Methanol v/v=100:1 eluate) with dichloromethane：Methanol is gradient elution agent, carries out pressured column silica gel
Analysis, merge after thin-layer chromatographic analysis and obtain five subfraction E1-E5.Component E2 (0.3 g) is with chloroform：Methanol=
1:2 be eluant, eluent, carries out gel filtration chromatography（Sephadex LH-20）, merge after thin-layer chromatographic analysis and obtain four subgroups
Divide E2-1 ~ E2-4.E2 subfraction E2-2 (93 mg) by semi-preparative liquid chromatography (1010 type ODS-A, 10 × 250 mm,
5 μm)：Separation flow velocity is 5 mL/min, and mobile phase is that 75% acetonitrile contains 0.1% TFA, obtains shown compound (3.4 mg, tR
9.1 min)。
It is yellow powder under compound normal temperature, high-resolution electrospray ionization mass spectrum HRESI-MS existsm/z: 383.1161 [M-H]
ˉ, calcd for C21H19O7, 383.1131, it is 384 to prompt molecular weight, speculates that molecular formula is with reference to spectral information
C21H20O7。1H and13C-NMR data are shown in Table 1, and main COSY, HMBC and NOE signal is shown in Fig. 1.
The compound of table 11H and13C-NMR data (500 MHz1H and 126 MHz 13C, in DMSO-d 6 )
The test of the anti tumor activity in vitro of embodiment 2
1 laboratory sample and experimental method
The preparation test sample of sample solution is the pure compounds of separation and purification in above-described embodiment 1.Precision weighs suitable
Sample is measured, the solution of concentration needed for methanol is configured to, for surveying activity.
The squamous subculture of cell line and cell uses tumor cell line, and tumour cell uses the DMEM containing 10% FBS to cultivate
Base, at 37 DEG C in being passed through 5% CO2Incubator in squamous subculture.
Cell inhibitory effect activity test method
Tetrazolium（MTT）Method is taken the logarithm the tumour cell in growth period, and cell density is adjusted into every milliliter 1 × 105Individual cell,
It is inoculated in by every μ L of hole 200 in 96 porocyte culture plates, 5% CO is passed through in 37 DEG C2Incubator in cultivate 4h.2 μ are added per hole
L sample liquid or blank solution, after cultivating 24h, MTT liquid is added per hole（MTT every mL5mg normal saline solutions）10 μ L,
Continue to cultivate 4h, 37 DEG C, 2000 turns/min centrifugation 8min, draw supernatant.Each 100 μ L of DMSO are added per hole, in micro oscillator
Upper vibration 15min, after being completely dissolved to crystallization, determined using the SPECTRAMAX Plus types ELIASA of MD companies production every
Extinction of the hole at 570 nm（OD）Value.Each concentration of sample is respectively provided with three holes in the orifice plate of same 96, another to set three holes
Blank control and acellular withered hole（It is acellular withered that if medicine has color to do relative medicine concentration）.Each hole OD values are first
Do corresponding acellular withered, then take three hole mean OD values by IR (%)=(ODBlank control-ODSample)/ODBlank control× 100% calculates often
The proliferation inhibition rate of cell under individual concentration（IR%）.
2. experimental result
Cell inhibitory effect active testing result
In mtt assay test, according to the Cytostatic to tumor cell rate of the compound of various concentrations, using SPSS16.0 softwares
Carry out data processing and calculation of half inhibitory concentration IC50Value.It the results are shown in Table 2.
Inhibitory activity of the compound of table 2 to Proliferation of Human Colon
3. conclusion
The compound has preferable antitumor activity to human colon cancer cell.It can be used as and prepare Proliferation of Human Colon suppression
Medicine or antineoplastic are used for the research of human colon carcinoma.
Claims (4)
1. compound。
2. the preparation method of compound as claimed in claim 1, it is characterised in that：Fermented and cultured aspergillus versicolor, fermentate is obtained,
Then the compound is isolated and purified out from fermentate, the aspergillus versicolor (Aspergillus versicolor) IBPT-
7, it is deposited in China typical culture collection center, address on December 25th, 2013:Wuhan Wuhan University, deposit number
It is：CCTCC NO：M 2013715.
3. compound described in claim 1 is preparing the application in suppressing Proliferation of Human Colon medicine.
4. application of the compound in anti-human colon cancer drug is prepared described in claim 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711079824.2A CN107739361B (en) | 2017-11-06 | 2017-11-06 | Derived from aspergillus versicolor anthraquinone analog compound and prepare the application of anti-human colon cancer drug |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201711079824.2A CN107739361B (en) | 2017-11-06 | 2017-11-06 | Derived from aspergillus versicolor anthraquinone analog compound and prepare the application of anti-human colon cancer drug |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN107739361A true CN107739361A (en) | 2018-02-27 |
| CN107739361B CN107739361B (en) | 2019-06-25 |
Family
ID=61233198
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201711079824.2A Active CN107739361B (en) | 2017-11-06 | 2017-11-06 | Derived from aspergillus versicolor anthraquinone analog compound and prepare the application of anti-human colon cancer drug |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN107739361B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108753627A (en) * | 2018-06-15 | 2018-11-06 | 河北大学 | A kind of marine aspergillus source oxa- anthraquinone analog compound and preparation method thereof and the application in preparing antitumor agent |
| CN115232096A (en) * | 2022-06-15 | 2022-10-25 | 福建卫生职业技术学院 | Lactone compound derived from aspergillus tenuissima, preparation method thereof and application thereof in anti-human liver cancer drugs |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104478891A (en) * | 2014-12-18 | 2015-04-01 | 福州大学 | Penicillium citrinum sourced citrinin compound (penicitrinol O) as well as preparation method and application thereof |
-
2017
- 2017-11-06 CN CN201711079824.2A patent/CN107739361B/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104478891A (en) * | 2014-12-18 | 2015-04-01 | 福州大学 | Penicillium citrinum sourced citrinin compound (penicitrinol O) as well as preparation method and application thereof |
Non-Patent Citations (2)
| Title |
|---|
| 邢倩等: "１株海洋来源真菌Ｎｉｇｒｏｓｐｏｒａｓｐ．蒽醌类化合物及其生物活性研究", 《中国海洋药物》 * |
| 霍娟等: "海洋生物内生真菌中蒽醌类次生代谢产物的研究", 《中国海洋药物杂志》 * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108753627A (en) * | 2018-06-15 | 2018-11-06 | 河北大学 | A kind of marine aspergillus source oxa- anthraquinone analog compound and preparation method thereof and the application in preparing antitumor agent |
| CN108753627B (en) * | 2018-06-15 | 2022-04-22 | 河北大学 | Marine aspergillus derived oxaanthraquinone compound, preparation method thereof and application thereof in preparation of antitumor agent |
| CN115232096A (en) * | 2022-06-15 | 2022-10-25 | 福建卫生职业技术学院 | Lactone compound derived from aspergillus tenuissima, preparation method thereof and application thereof in anti-human liver cancer drugs |
| CN115232096B (en) * | 2022-06-15 | 2023-05-05 | 福建卫生职业技术学院 | Lactone compound from aspergillus flavus, preparation method thereof and application thereof in anti-human liver cancer drugs |
Also Published As
| Publication number | Publication date |
|---|---|
| CN107739361B (en) | 2019-06-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107298671B (en) | Selenolonic acid H from penicillium oxalicum and application thereof in preparing medicine for resisting human colon cancer | |
| CN107353274A (en) | Come from the secalonic acid I of penicillium oxalicum and prepare the application of anti-human oesophagus cancer drug | |
| CN107298672B (en) | Application of seclenic acid I derived from penicillium oxalicum in preparation of anti-human colon cancer drugs | |
| CN107298670B (en) | Application of medicine derived from penicillium oxalicum seclenum ketonic acid H in preparation of anti-human oral epidermoid carcinoma medicines | |
| CN107485607A (en) | The secalonic acid H for coming from penicillium oxalicum is preparing the application of anti-human oesophagus cancer drug | |
| CN107739361B (en) | Derived from aspergillus versicolor anthraquinone analog compound and prepare the application of anti-human colon cancer drug | |
| CN107739362B (en) | Derived from aspergillus versicolor anthraquinone analog compound and prepare the application of anti-human oesophagus cancer drug | |
| CN107298669B (en) | Selenolonic acid I from penicillium oxalicum and application of medicine for resisting human oral epidermoid carcinoma | |
| CN111004251B (en) | Marine-derived heteroterpene compounds I and II, preparation method and application thereof in preparation of antitumor drugs | |
| CN109106702A (en) | Derived from application of 4-4 ' the isomerization secalonic acid D in terms of colon cancer of penicillium oxalicum | |
| CN105061446B (en) | Penicillium citrinum-derived penicitrinine A as well as application thereof to preparation of drugs for resisting nasopharyngeal carcinoma | |
| CN110407792A (en) | Derived from the secalonic acid class compound Secalonic acid J and preparation method of penicillium oxalicum | |
| CN109134416B (en) | Application of seclenic acid H derived from penicillium oxalicum in preparation of human cervical cancer drugs | |
| CN109776477A (en) | Iso-Penicillixanthone A and anti-vincristine drug resistance application derived from penicillium oxalicum | |
| CN110407794B (en) | Selenolonic acid K derived from penicillium oxalicum and application thereof in inhibiting cancer cell proliferation | |
| CN104211780B (en) | A kind of cyclic depsipeptides compound and its production and use | |
| CN110407797A (en) | Derived from the secalonic acid class compound Secalonic acid K and preparation method of penicillium oxalicum | |
| CN115227691B (en) | Application of lactone compound from aspergillus flavus in anti-human breast cancer medicine | |
| CN104447475B (en) | Preparation method and application of penicillenol D1 derived from penicillium citrinum | |
| CN115232096B (en) | Lactone compound from aspergillus flavus, preparation method thereof and application thereof in anti-human liver cancer drugs | |
| CN109134417A (en) | Derived from the application of the secalonic acid I and anti-human cervix cancer drug of penicillium oxalicum | |
| CN110407796A (en) | Derived from the secalonic acid class compound Secalonic acid L and preparation method of penicillium oxalicum | |
| CN105017272B (en) | Penicitrinine A originated from penicillium citrinum and application thereof in preparation of anti human breast cancer drugs | |
| CN110407793A (en) | Secalonic acid J derived from penicillium oxalicum and the application on inhibition cancer cell multiplication | |
| CN106491596B (en) | Derived from application of the mould enol E1 in terms of lung cancer of tangerine green trichoderma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |